Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Bicalutamide improved hair growth more than spironolactone in women with hair loss.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

Combining betamethasone and PRP injections works best for treating alopecia areata.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

The microneedle system effectively promotes hair growth for treating androgenic alopecia.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Oral prednisolone helps hair regrowth in alopecia areata.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

AMP-303 safely increases hair growth in men with hair loss.